Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater collaboration between Mexican universities and the pharmaceutical industry to bring more life-changing innovation to patients.
Could you please provide our readers with a general overview of the Institute of Biomedical Research?
We truly take a holistic approach to our research, always trying to cultivate new ways to view and treat diseases.
Recently appointed CEO and president for Pfizer Mexico, Constanza Losada, outlines the exciting challenge of taking on leadership for such an important affiliate during the COVID-19 pandemic and how Pfizer…
UCB’s Omar Lugo Aguirre outlines the company’s response to the COVID-19 pandemic in Mexico, countering stigmas around neurodegenerative and mental diseases, and the abundant opportunities that Mexico and the region…
Biogen Mexico’s Luis Calderon discusses establishing the affiliate, the opportunities apparent in the Mexican neurodegenerative disease market, and the impact of the country’s ongoing health reforms. In my experience,…
Writing in the January edition of DIA’s Global Forum magazine, Julia Chan, David Liew, Jana Stojanova, and Chris McMaster of Austin Health, Melbourne and St. Vincent’s Hospital Sydney outline how…
PPC China’s Sophia Duan, writing in the January edition of DIA’s Global Forum magazine, details how the emergence of an effective pharmacovigilance ecosystem is helping to safeguard the rollout of…
According to recent IQVIA and industry association reports, the Spanish pharma market, valued at EUR 21.6 billion per year, continues to grow at a relatively slow pace. Other key trends…
See our Cookie Privacy Policy Here